Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Carvedilol · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Carvedilol Tablets 12.5 mg |
| 2 | ACTIVE_COMPARATOR | Coreg® Tablets 12.5 mg |
| Name | Type | Description |
|---|---|---|
| Carvedilol Tablets 12.5 mg | DRUG | 12.5mg, single dose fed |
| Coreg® Tablets 12.5 mg | DRUG | 12.5mg, single dose fed |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have negative serum beta human chorionic gonadotropin (beta-HCG) pregnancy tests performed within 14 days prior to the start of the study and on the ev...
Carvedilol is a small molecule drug candidate developed by Viatris Inc. (ticker: VTRS). It is being studied in Phase 1 clinical development. The specific therapeutic indication for this program is undisclosed, and the therapeutic area is classified as Other.
Carvedilol targets the alpha-1 adrenergic receptors ADRA1A, ADRA1B, and ADRA1D, as well as the beta-adrenergic receptors ADRB1, ADRB2, and ADRB3. It acts as an antagonist at these targets, meaning it blocks receptor activity.
Carvedilol is developed by Viatris Inc., which trades under the ticker symbol VTRS. Viatris is the sponsor responsible for the clinical development of this asset.
Carvedilol is in Phase 1 clinical development. It is an investigational drug candidate and has not been approved by the FDA for the undisclosed indication being studied. Two Phase 1 trials have been completed, and no active trials are currently listed.
Carvedilol has been evaluated in two completed Phase 1 trials: NCT00650416, a fasting study comparing Carvedilol Tablets 12.5 mg to Coreg Tablets 12.5 mg, and NCT00648622, a fed study with the same comparison. Both enrolled 50 healthy volunteers in the United States.